The treatment and prevention of thrombosis is currently under a period of rapid change with the replacement of traditional anticoagulant vitamin K antagonists with direct oral anticoagulants (DOACs), which specifically target factors FXa or FIIa.
Introduction
Therapeutic targeting of blood coagulation is an inherently difficult task as it interferes with the delicate balance of pro-and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year to limit the otherwise essential function of blood clotting 1 . However this intervention inevitably leads to an elevated risk of undesired bleeding.
While some bleeding events are clinically mild and less critical, others can be life threatening, such as intracranial or abdominal bleeding.
The dichotomy of therapies targeting the hemostatic system is also evidenced in hemophilic coagulopathies, where blood coagulation is insufficient. In these cases the treatment of acquired or inherited hemophilia requires substitution of the lacking blood coagulation factor(s), ideally without tilting the hemostatic system too far towards a procoagulant state with eventual predisposition to thrombosis 2 .
The treatment and prevention of thrombosis is currently under a period of rapid change. Direct oral anticoagulants (DOACs), which specifically target blood coagulation factors FXa (Rivaroxaban, Apixaban, Edoxaban) or FIIa (Dabigatran), are replacing traditional anticoagulants, such as vitamin K antagonists which impair the biosynthesis of factors FII, FVII, FIX and FX ( Figure 1A ). Nevertheless, satisfying therapeutic options are still lacking for a growing population with comorbidities who exhibit an increased risk of bleeding with DOAC treatment. These include patients with moderate to severe renal failure, hepatic failure, mechanic heart valve or patients under therapy with CYP3A4 and P-Glycoprotein inhibitors [4] [5] [6] [7] .
This elevated risk primarily reflects interference with metabolic turnover or excretion mechanisms of the DOAC. Finally DOACs may be associated with an increased risk in patients with antiphospholipid syndrome (APS) 3 limiting their use in this critical population with a significant risk of thromboembolic events.
Results and Discussion
Recently a series of articles have documented the targeting of factors FXI and FXII as increasingly evolving new therapeutic strategies [4] [5] [6] [7] [8] . The rationale behind this approach is that both components, FXI and FXII, belong to the so-called "contact system", which appears to play an important role in thrombosis, however they are more or less functionally dispensable for hemostasis [9] [10] [11] (Figure 1A ). It is hoped that this approach may overcome functional obstacles in the quest for the 'ideal anticoagulant', that of treating or preventing thrombosis without affecting hemostasis. A key question in following up this approach is which of these two factors is likely to be the more reliable target in the challenging endeavor of inhibiting blood clotting while maintaining hemostasis?
Here we present an interdisciplinary contribution to this exciting discussion from the area of RNA biology providing a novel avenue for the therapeutic targeting of FXI. Based on the data generated in a recent large-scale determination of functional miRNAs targeting the hemostatic system in the search for novel and rationale therapeutic targets 12 , we find FXI to be targeted by the largest number of miRNAs, while FXII does not appear to be regulated by miRNAs (Table 1 ).
This observation is consistent with further miRNAs reported to target FXI [13] [14] [15] , while no reports are found for factor FXII. Biologically, this finding is remarkable. It suggests that FXI expression is under tight control via 3'UTR mediated regulation to ensure modest levels of FXI protein while FXII is not. This is in line with tighter regulation reflected by the leptokurtic distribution (i.e. narrower range) and lower percent coefficient variation (%CV) of FXI plasma levels as compared to FXII in our cohort ( Figure 1B) , which is consistent with earlier observations 16 . The biological importance is corroborated by the functional consequences in patients where elevated FXI levels predispose to thrombosis [17] [18] [19] , while patients with FXI deficiency are protected from venous thromboembolism (VTE) and ischemic stroke 20 . Further support for the regulatory importance of the FXI 3'UTR comes from a recent study in which 3'UTR single nucleotide polymorphisms were found to be associated with plasma FXI activity and risk of venous thrombosis 13 . Remarkably while the FXII 3'UTR is relatively short (~150 nucleotides; nt) the FXI 3'UTR spans over ~1000 nt. In addition to the high number of miRNAs, using RNA affinity pull-downs coupled to mass spectrometry we identify here that the FXI 3'UTR also binds numerous RNA binding proteins (RBPs) in close proximity to, and sometimes even in the direct target region of miRNAs ( Figure   1C -D).
With regards to the important question as to which of the two components of the upstream intrinsic pathway (FXI or FXII) is likely to be the better therapeutic target, our data suggests that the specific miRNA mediated control of FXI may be a hitherto unrecognized rationale for the therapeutic targeting of FXI. Additionally it may provide a novel avenue for this targeting.
While a number of FXI inhibitors, including polypeptides, active site peptidomimetic inhibitors, allosteric inhibitors, antibodies, aptamers and antisense oligonucleotides (ASOs), have been proposed 21 , it is important to realize that by mimicking the endogenous function of miRNAs to limit excessive expression, therapeutic miRNA delivery may possibly reflect a more physiological state in limiting FXI levels to treat and prevent VTE while retaining sufficient hemostasis for the prevention of bleeding. Although miRNA targeting to silence FXI could potentially have off-target effects, the functional synergy of several targeting miRNAs in a therapeutic cocktail allows for an increase in effect size and a reduction in side effects 12 . Finally and most importantly, miRNAmediated targeting may also preserve cell intrinsic regulatory mechanisms, such as modulated 'occlusion' of miRNA binding sites by RNA binding proteins (RBPs) [22] [23] [24] , regulation through other noncoding RNAs or interaction with competing endogenous (ce)RNAs (i.e. miRNA sponges, circRNA) as well as other regulatory mechanisms 25 , ensuring the normal physiological fine tuning of the availability of the factor is maintained 26 (Figure 1E ). Thus even in the presence of the miRNA therapeutic, RBP-mediated regulation (and other posttranscriptional gene regulatory mechanisms) may be in place to evade miRNA-mediated silencing for example in order to stock pile blood clotting factors in an acute event of blood loss.
We thus believe that despite the impressive 'juggernaut' of anticoagulants, there are untapped therapeutic options that can help meet unmet medical needs. miRNA based therapeutics, currently emerging as attractive therapies in many other disciplines 27 , may represent an avenue for correction of de-regulated hemostasis and associated processes in the future. Given the plethora of miRNA based therapeutic possibilities, such as miRNA mimicking, silencing, target specific miRNA target site blockers, knowledge of the miRNA targetome in the hemostatic system is potentially a major trove for future targeted therapeutics, not only for the development of safe anticoagulants but also for developing treatments for coagulopathies. In aid of these endeavors the first comprehensive hemostatic miRNA targetome is provided as a repository accompanying our recent paper 12 .
Future studies are urgently needed to test this therapeutic principle in a clinical setting. This is particularly applicable in hemostaseology where monitoring of therapeutic effects remains a daily routine and thus assessment of the efficacy and safety of such therapeutic components could be simply implemented ushering in a novel therapeutic era with broad applicability. Finally, although we have previously demonstrated the in-principal drugability of the hemostatic system in a miRNA-directed manner using intravenously administered LNA oligonucleotides 12 , future therapies would ideally require a more convenient oral delivery route. This may be accomplished through novel delivery vehicles that allow oral miRNA uptake, for example milk exosomes 28 .
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The authors declare no competing financial interests. Table 1 . A. Functional miRNAs targeting the hemostatic system. The first two columns are based on the hemostatic miRNA targetome identified in Nourse et. al. 12 by miTRAP RNA pulldowns. The first column indicates interactions validated by functional miRNA-mimic-rescue luciferase assays, while the second column indicates interactions identified by miTRAP RNA pull-down alone 12 The emerging picture is that of complex and multifaceted layers of 3'UTR-mediated regulation, including competition and cooperativity of these regulatory components, to adjust protein synthesis in a spatiotemporal manner 24, 25 . Of note such mechanisms also tune the hemostatic system, for example in an acute event of blood loss to stock pile blood coagulation factors 29 . As opposed to ASO silencing, and in many cases siRNAs, (right), which inevitably results in degradation of the target mRNA, the partial base-pairing of miRNAs (left) prevents the cleavage activity of RISC with silencing predominately resulting from translational repression, and in some cases deadenylation, decapping and finally mRNA degradation 30 . This appears to be particularly relevant for secretory proteins (such as components of the hemostatic system) produced at the endoplasmicreticulum 31 . Thus, miRNA-mediated therapeutic targeting without degradation of such target mRNAs preserves cell intrinsic regulatory mechanisms executed by 3'UTRs and their 'interacting partners' such as RBPs, miRNAs and/or other layers of control, such as ceRNA, circRNA miRNA sponges. Finally miRNA sites in proximity to RBP sites are often subject to mechanisms of physiological control [22] [23] [24] [25] , which may play important regulatory roles to control the delicate balance of hemostatic system in response to environmental cues 29 .
